Methotrexate Accord (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for converting folic acid into its active form. This inhibition reduces the synthesis of DNA, RNA, and proteins, limiting the proliferation of malignant cells and dampening the activity of immune cells that drive inflammation.

The prescribed dose of Methotrexate Accord is individualized by the treating physician based on the specific indication, disease severity, patient weight, renal and hepatic function, and prior response to therapy. Only a qualified healthcare professional should set the dosing regimen.

Methotrexate is classified as a high‑risk teratogen and is contraindicated during pregnancy because it can cause fetal malformations and loss. It is also excreted in breast milk, so breastfeeding is generally not recommended while receiving the drug.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Compared with biologic agents, methotrexate is a small‑molecule drug that can be administered via injection or orally, offering a lower cost and broader availability. However, biologics may have a more targeted mechanism with different safety profiles, while methotrexate’s efficacy is well‑established across several indications.

Methotrexate Accord should be stored at ambient temperature, below 25 °C, in its original container. Protect the product from moisture, direct sunlight, and extreme temperatures to maintain stability and potency throughout its shelf life.

Methotrexate Accord is supplied for parenteral use and can be given intramuscularly, intravenously, or intrathecally by a qualified healthcare professional. The route and infusion rate are selected according to the clinical indication and patient tolerance.

Serious risks include severe liver toxicity, pulmonary fibrosis, profound bone‑marrow suppression leading to pancytopenia, acute kidney injury, and life‑threatening infections. Patients should be monitored regularly for signs of organ dysfunction and infection, and therapy should be stopped if severe adverse events occur.

Methotrexate Accord is contraindicated in patients with known hypersensitivity to methotrexate, severe hepatic or renal impairment, active infections, and in women who are pregnant or planning pregnancy. Caution is also advised for individuals with pre‑existing lung disease or immunodeficiency.